Overview of new combinaton therapies in acute myeloid leukemia (AML)

At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University of Texas MD Anderson Cancer Center, Houston, TX, provides an overview of new combination therapies involving hypomethylating agents. Dr Daver focuses on the following combinations: decitabine and vosarocin; decitabine and venetoclax (ABT-199); cytarabine and SGN-CD33A a CD33a monoclonal antibody .

Share this video